IMI and McNeil expand marketing partnership for heart disease predictive test
Predictive medicine company IMI International Medical Innovations Inc has expanded its marketing partnership with McNeil Consumer Healthcare to include the laboratory market for insurance testing throughout the U.S., Canada and Mexico.
"The market for insurance testing represents a significant new opportunity for our predictive heart disease test throughout North America," said Dr. Brent Norton, IMI President and CEO. "Millions of insurance policies are granted each year without a cardiovascular risk assessment, and now through our simple skin test McNeil can begin to exploit that strategic opportunity."
"Our relationship with McNeil continues to grow. Together we are building toward market launches and developing new test formats for specific market opportunities to maximize the potential for the technology," said Dr. Norton.